Clinical development failure
The company has no approved products, so value depends on positive trial readouts and tolerability.
- Scope
- dabogratinib, TYRA-200, TYRA-430
- Materiality
- high
Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on precision medicines for oncology and genetically defined conditions. Its pipeline centers on oral small-molecule programs that target fibroblast growth factor receptor (FGFR) biology, including dabogratinib and TYRA-200, supported by its proprietary SNÅP drug-design platform.
14.67
14.67
| % | |
|---|---|
| Clinical-stage drug candidates | 0% Oral small-molecule programs in clinical development for FGFR-driven cancers and related conditions. |
| Discovery platform | 0% SNÅP is the internal drug-design platform used to generate and optimize new candidates. |
| Preclinical pipeline | 0% Undisclosed early-stage programs focused on FGFR biology and other precision-oncology targets. |
Tyra Biosciences does not currently sell commercial products; its near-term 'customers' are clinical trial...
- Clinical trial patientsprimary
Patients with FGFR-altered cancers or genetic conditions enrolled in studies of TYRA-200, TYRA-430, and dabogratinib.
- Clinical investigators and trial sitesprimary
Hospitals and research centers that recruit patients, administer study drugs, and generate safety/efficacy data.
- Future oncology prescriberssecondary
Oncologists who would prescribe approved FGFR-targeted therapies for urothelial cancer, ICC, HCC, and other tumors.
- Future specialty-care physicianssecondary
Physicians treating skeletal dysplasia who could use dabogratinib if it reaches that indication.
Tyra Biosciences is headquartered in the United States and conducts development work through a clinical-trial network...
- •Headquartered in the United States
- •Clinical development is run through multicenter trial sites
- •Trial geography can expand with patient-enrollment needs
- •Future commercialization would depend on major market approvals
- •Potential manufacturing and supply-chain exposure may include China
Tyra Biosciences is building a wholly owned pipeline around FGFR biology, using its SNÅP platform to design more...
01
Advance lead clinical programsshort-term
Clinical proof-of-concept is the main value driver for a pre-revenue biotech.
02
Differentiate through selectivity and resistance coveragemedium-term
Better selectivity and resistance handling can improve efficacy and tolerability versus older FGFR drugs.
03
Expand the SNÅP discovery enginelong-term
A productive platform can create multiple shots on goal beyond the current pipeline.
Tyra Biosciences faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory delays, and...
Regulatory and approval risk
Even promising data may not translate into marketing approval or label breadth.
- Scope
- all pipeline programs
- Materiality
- high
Competitive displacement
Other FGFR and oncology therapies may be more effective, safer, or faster to market.
- Scope
- FGFR-targeted oncology
- Materiality
- high
Third-party manufacturing and CRO dependence
The company relies on external partners for clinical supply and trial execution.
- Scope
- clinical and preclinical programs
- Materiality
- medium
China sourcing and trade restrictions
Use of foreign contract manufacturers can be affected by tariffs, sanctions, and U.S. restrictions.
- Scope
- manufacturing supply chain
- Materiality
- medium
Accrued research and development expenses
Can move quarterly operating expense and liabilities
Stock-based compensation
Affects operating loss and equity dilution
Marketable securities valuation and interest income
Affects other income and liquidity presentation
: 29.4.2026